Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
Calidi Biotherapeutics (NYSE American: CLDI) is developing a next-generation platform for cancer treatment using engineered viruses to deliver genetic medicines directly to tumors. The company's innovative approach targets both primary and metastatic tumors, addressing a critical healthcare need as cancer diagnoses are projected to reach 35 million annually by 2050.
While initially focused on oncology, Calidi is also exploring applications in autoimmune disorders. This development comes as global cancer cases reach 20 million diagnoses and 10 million deaths annually, highlighting the urgent need for more effective treatment options.
Calidi Biotherapeutics (NYSE American: CLDI) sta sviluppando una piattaforma di nuova generazione per il trattamento del cancro, utilizzando virus ingegnerizzati per veicolare direttamente medicinali genetici nei tumori. L'approccio innovativo dell'azienda mira sia ai tumori primari che a quelli metastatici, rispondendo a un'esigenza sanitaria critica dato che le diagnosi di cancro sono previste raggiungere 35 milioni all'anno entro il 2050.
Pur concentrandosi inizialmente sull'oncologia, Calidi sta anche esplorando applicazioni nelle malattie autoimmuni. Questo sviluppo arriva in un contesto in cui i casi globali di cancro raggiungono 20 milioni di diagnosi e 10 milioni di decessi all'anno, sottolineando l'urgenza di opzioni terapeutiche più efficaci.
Calidi Biotherapeutics (NYSE American: CLDI) está desarrollando una plataforma de próxima generación para el tratamiento del cáncer, utilizando virus diseñados para entregar medicamentos genéticos directamente a los tumores. El enfoque innovador de la compañía apunta tanto a tumores primarios como metastásicos, atendiendo una necesidad crítica en salud ya que se proyecta que los diagnósticos de cáncer alcancen 35 millones anuales para 2050.
Aunque inicialmente se enfoca en oncología, Calidi también está explorando aplicaciones en trastornos autoinmunes. Este desarrollo surge en un contexto donde los casos globales de cáncer alcanzan 20 millones de diagnósticos y 10 millones de muertes anuales, resaltando la urgente necesidad de opciones de tratamiento más efectivas.
Calidi Biotherapeutics (NYSE American: CLDI)는 암 치료를 위한 차세대 플랫폼을 개발하고 있으며, 유전자 치료제를 종양에 직접 전달하기 위해 설계된 바이러스를 사용합니다. 이 회사의 혁신적인 접근법은 원발성 및 전이성 종양 모두를 목표로 하여, 2050년까지 연간 3,500만 건에 이를 것으로 예상되는 암 진단에 대응하는 중요한 의료 수요를 충족합니다.
초기에는 종양학에 집중했지만, Calidi는 자가면역 질환에도 적용 가능성을 탐구하고 있습니다. 전 세계적으로 암 진단이 2,000만 건, 연간 1,000만 명의 사망에 이르는 상황에서, 보다 효과적인 치료법의 긴급한 필요성을 강조합니다.
Calidi Biotherapeutics (NYSE American : CLDI) développe une plateforme de nouvelle génération pour le traitement du cancer, utilisant des virus modifiés pour délivrer directement des médicaments génétiques aux tumeurs. L'approche innovante de l'entreprise cible à la fois les tumeurs primaires et métastatiques, répondant à un besoin crucial de santé publique alors que les diagnostics de cancer devraient atteindre 35 millions par an d'ici 2050.
Bien que l'entreprise se concentre initialement sur l'oncologie, Calidi explore également des applications dans les maladies auto-immunes. Ce développement intervient alors que les cas mondiaux de cancer atteignent 20 millions de diagnostics et 10 millions de décès par an, soulignant l'urgence de disposer d'options de traitement plus efficaces.
Calidi Biotherapeutics (NYSE American: CLDI) entwickelt eine Plattform der nächsten Generation zur Krebsbehandlung, bei der gentechnisch veränderte Viren eingesetzt werden, um genetische Medikamente direkt an Tumoren zu liefern. Der innovative Ansatz des Unternehmens richtet sich sowohl gegen primäre als auch metastatische Tumore und adressiert einen kritischen Gesundheitsbedarf, da die Krebsdiagnosen bis 2050 voraussichtlich 35 Millionen jährlich erreichen werden.
Obwohl der Fokus zunächst auf der Onkologie liegt, untersucht Calidi auch Anwendungen bei Autoimmunerkrankungen. Diese Entwicklung erfolgt vor dem Hintergrund, dass weltweit jährlich 20 Millionen Krebsdiagnosen und 10 Millionen Todesfälle verzeichnet werden, was die dringende Notwendigkeit effektiverer Behandlungsmöglichkeiten unterstreicht.
- None.
- None.
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers,” please visit: https://nnw.fm/zBrXc.
Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades (https://ibn.fm/dyQrw). By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant.
Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors. Using engineered viruses to transport therapeutic payloads with precision, Calidi’s technology aims to transform the landscape of cancer treatment. Though oncology is its initial focus, the company is also exploring broader applications in high-need areas such as autoimmune disorders. In doing so, Calidi is positioning itself among a select group of biotech innovators
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical-stage, off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
For more information, visit the company’s website at www.calidibio.com .
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
FAQ
What is Calidi Biotherapeutics' (CLDI) approach to cancer treatment?
What is the market potential for Calidi Biotherapeutics' (CLDI) cancer treatment platform?
What other therapeutic areas is Calidi Biotherapeutics (CLDI) exploring beyond cancer?
How many people are affected by cancer globally according to CLDI's release?
